European Heart Journal Supplements最新文献_第5页

May Measurement Month 2021: an analysis of blood pressure screening results from the UK and Republic of Ireland. 2021 年五月测量月：英国和爱尔兰共和国血压筛查结果分析。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-24 eCollection Date: 2024-06-01 DOI: 10.1093/eurheartjsupp/suae060

Shaun C Lee, Daniel Warrington, Thomas Beaney, John R Cockcroft, Christopher J A Pugh, Abbie Williams, Tyler Olding, Eamon Dolan, Eoin O'Brien, Lisa Hynes, Madeline Rabbitt, Paul Cunnane, Aletta E Schutte, Neil R Poulter, Barry J McDonnell

{"title":"May Measurement Month 2021: an analysis of blood pressure screening results from the UK and Republic of Ireland.","authors":"Shaun C Lee, Daniel Warrington, Thomas Beaney, John R Cockcroft, Christopher J A Pugh, Abbie Williams, Tyler Olding, Eamon Dolan, Eoin O'Brien, Lisa Hynes, Madeline Rabbitt, Paul Cunnane, Aletta E Schutte, Neil R Poulter, Barry J McDonnell","doi":"10.1093/eurheartjsupp/suae060","DOIUrl":"10.1093/eurheartjsupp/suae060","url":null,"abstract":"We participated in the UK and Republic of Ireland May Measurement Month 2021 (MMM21) campaign to raise awareness about blood pressure (BP) measurement and the dangers posed by elevated BP and hypertension. In addition, the campaign aimed to collect and report levels of BP awareness and control in the community setting. The MMM21 campaign set up opportunistic community screening sites at hospitals, general practice (GP) surgeries, community pharmacies, gyms, and various other public places. The campaign screened 1322 participants (mean age 46 years, 55% women) and found that 522 (39.5%) had hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or on antihypertensive medication) at the time of testing. Of the 522 participants identified with hypertension, only 47.2% were aware of their condition. Of those on antihypertensive medication, only 45.7% had controlled BP (systolic BP < 140 mmHg and diastolic BP < 90 mmHg), and of all hypertensives, only 19.0% were controlled. Our UK and Ireland data continue to shed further light on low levels of awareness and control of hypertension in the UK and Ireland community setting. This evidence supports a critical need to further highlight the importance of identifying and taking action against raised BP.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Intracoronary imaging to guide percutaneous coronary intervention: from evidence to guidelines; Controversy in cardiology: clopidogrel or acetylsalicylic acid in the treatment of chronic coronary syndromes? 更正：冠状动脉内成像指导经皮冠状动脉介入治疗：从证据到指南；心脏病学中的争议：治疗慢性冠状动脉综合征时使用氯吡格雷还是乙酰水杨酸？

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-18 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae079

引用次数: 0

Correction to: Screening for dilated cardiomyopathy in immediate family members: to whom, how, when (and where). 更正：直系亲属扩张型心肌病筛查：筛查对象、筛查方式、筛查时间（以及筛查地点）。

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-18 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae080

引用次数: 0

Cardio-oncology rehabilitation: are we ready? 心脏肿瘤康复：我们准备好了吗？

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-16 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae030

Irma Bisceglia, Elio Venturini, Maria Laura Canale, Marco Ambrosetti, Carmine Riccio, Francesco Giallauria, Giuseppina Gallucci, Maurizio G Abrignani, Giulia Russo, Chiara Lestuzzi, Raffaella Mistrulli, Giovanni De Luca, Fabio Maria Turazza, Gianfrancesco Mureddu, Stefania Angela Di Fusco, Fabiana Lucà, Leonardo De Luca, Andrea Camerini, Geza Halasz, Massimiliano Camilli, Vincenzo Quagliariello, Nicola Maurea, Francesco Fattirolli, Michele Massimo Gulizia, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva

{"title":"Cardio-oncology rehabilitation: are we ready?","authors":"Irma Bisceglia, Elio Venturini, Maria Laura Canale, Marco Ambrosetti, Carmine Riccio, Francesco Giallauria, Giuseppina Gallucci, Maurizio G Abrignani, Giulia Russo, Chiara Lestuzzi, Raffaella Mistrulli, Giovanni De Luca, Fabio Maria Turazza, Gianfrancesco Mureddu, Stefania Angela Di Fusco, Fabiana Lucà, Leonardo De Luca, Andrea Camerini, Geza Halasz, Massimiliano Camilli, Vincenzo Quagliariello, Nicola Maurea, Francesco Fattirolli, Michele Massimo Gulizia, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva","doi":"10.1093/eurheartjsupp/suae030","DOIUrl":"10.1093/eurheartjsupp/suae030","url":null,"abstract":"Cardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation but also a pillar of preventive cardio-oncology. Cardio-oncology rehabilitation is a comprehensive model based on a multitargeted approach and its efficacy has been widely documented; when compared with an 'exercise only' programme, comprehensive CORE demonstrates a better outcome. It involves nutritional counselling, psychological support, and cardiovascular (CV) risk assessment, and it is directed to a very demanding population with a heavy burden of CV diseases driven by physical inactivity, cancer therapy-induced metabolic derangements, and cancer therapy-related CV toxicities. Despite its usefulness, CORE is still underused in cancer patients and we are still at the dawning of remote models of rehabilitation (tele-rehabilitation). Not all CORE is created equally: a careful screening procedure to identify patients who will benefit the most from CORE and a multidisciplinary customized approach are mandatory to achieve a better outcome for cancer survivors throughout their cancer journey. The aim of this paper is to provide an updated review of CORE not only for cardiologists dealing with this peculiar population of patients but also for oncologists, primary care providers, patients, and caregivers. This multidisciplinary team should help cancer patients to maintain a healthy and active life before, during, and after cancer treatment, in order to improve quality of life and to fight health inequities.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'. 意大利医院心脏病专家协会立场文件《性别差异：是时候实施基于性别的临床管理了》。

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-16 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae034

Fabiana Lucà, Daniela Pavan, Michele Massimo Gulizia, Maria Teresa Manes, Maurizio Giuseppe Abrignani, Francesco Antonio Benedetto, Irma Bisceglia, Silvana Brigido, Pasquale Caldarola, Raimondo Calvanese, Maria Laura Canale, Giorgio Caretta, Roberto Ceravolo, Alaide Chieffo, Cristina Chimenti, Stefano Cornara, Ada Cutolo, Stefania Angela Di Fusco, Irene Di Matteo, Concetta Di Nora, Francesco Fattirolli, Silvia Favilli, Giuseppina Maura Francese, Sandro Gelsomino, Giovanna Geraci, Simona Giubilato, Nadia Ingianni, Annamaria Iorio, Francesca Lanni, Andrea Montalto, Federico Nardi, Alessandro Navazio, Martina Nesti, Iris Parrini, Annarita Pilleri, Andrea Pozzi, Carmelo Massimiliano Rao, Carmine Riccio, Roberta Rossini, Pietro Scicchitano, Serafina Valente, Giuseppe Zuccalà, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva

{"title":"Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.","authors":"Fabiana Lucà, Daniela Pavan, Michele Massimo Gulizia, Maria Teresa Manes, Maurizio Giuseppe Abrignani, Francesco Antonio Benedetto, Irma Bisceglia, Silvana Brigido, Pasquale Caldarola, Raimondo Calvanese, Maria Laura Canale, Giorgio Caretta, Roberto Ceravolo, Alaide Chieffo, Cristina Chimenti, Stefano Cornara, Ada Cutolo, Stefania Angela Di Fusco, Irene Di Matteo, Concetta Di Nora, Francesco Fattirolli, Silvia Favilli, Giuseppina Maura Francese, Sandro Gelsomino, Giovanna Geraci, Simona Giubilato, Nadia Ingianni, Annamaria Iorio, Francesca Lanni, Andrea Montalto, Federico Nardi, Alessandro Navazio, Martina Nesti, Iris Parrini, Annarita Pilleri, Andrea Pozzi, Carmelo Massimiliano Rao, Carmine Riccio, Roberta Rossini, Pietro Scicchitano, Serafina Valente, Giuseppe Zuccalà, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva","doi":"10.1093/eurheartjsupp/suae034","DOIUrl":"10.1093/eurheartjsupp/suae034","url":null,"abstract":"It has been well assessed that women have been widely under-represented in cardiovascular clinical trials. Moreover, a significant discrepancy in pharmacological and interventional strategies has been reported. Therefore, poor outcomes and more significant mortality have been shown in many diseases. Pharmacokinetic and pharmacodynamic differences in drug metabolism have also been described so that effectiveness could be different according to sex. However, awareness about the gender gap remains too scarce. Consequently, gender-specific guidelines are lacking, and the need for a sex-specific approach has become more evident in the last few years. This paper aims to evaluate different therapeutic approaches to managing the most common women's diseases.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Italian Association of Hospital Cardiologists position paper-obesity in adults: a clinical primer. 意大利医院心脏病专家协会立场文件--成人肥胖症：临床入门。

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-16 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae031

Stefania Angela Di Fusco, Edoardo Mocini, Mauro Gori, Massimo Iacoviello, Claudio Bilato, Marco Corda, Leonardo De Luca, Massimo Di Marco, Giovanna Geraci, Attilio Iacovoni, Massimo Milli, Alessandro Navazio, Vittorio Pascale, Carmine Riccio, Pietro Scicchitano, Emanuele Tizzani, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva

{"title":"Italian Association of Hospital Cardiologists position paper-obesity in adults: a clinical primer.","authors":"Stefania Angela Di Fusco, Edoardo Mocini, Mauro Gori, Massimo Iacoviello, Claudio Bilato, Marco Corda, Leonardo De Luca, Massimo Di Marco, Giovanna Geraci, Attilio Iacovoni, Massimo Milli, Alessandro Navazio, Vittorio Pascale, Carmine Riccio, Pietro Scicchitano, Emanuele Tizzani, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva","doi":"10.1093/eurheartjsupp/suae031","DOIUrl":"10.1093/eurheartjsupp/suae031","url":null,"abstract":"Obesity is a chronic and relapsing disease characterized by the interaction between individual predispositions and an obesogenic environment. Recent advances in understanding the mechanisms of energetic homoeostasis paved the way to more effective therapeutic approaches compared with traditional treatments. Since obesity is a complex disease, it necessitates a multi-disciplinary approach whose implementation remains challenging. Nonetheless, emerging pharmacological interventions appear promising. Currently, therapeutic success is discreet in the short term but often fails to maintain long-term weight loss due to a high likelihood of weight regain. Cardiologists play a key role in managing patients with obesity, yet often lack familiarity with its comprehensive management. The aim of this document is to summarize knowledge to consolidate essential knowledge for clinicians to effectively treat patients living with obesity. The paper emphasizes the pivotal role of a strong patient-clinician relationship in navigating successful treatment. We analyse the criteria commonly used to diagnose obesity and point out the strengths and limitations of different criteria. Furthermore, we discuss the role of obesiologists and the contributions of cardiologists. In addition, we detail key components of effective therapeutic strategies, including educational aspects and pharmacological options.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events. ANMCO/SIMEU 关于在持续出血或出血事件高风险患者中使用抗血栓疗法逆转剂的共识文件。

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-16 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae033

Leonardo De Luca, Francesco Rocco Pugliese, Beniamino Susi, Alessandro Navazio, Marco Corda, Andrea Fabbri, Pietro Scicchitano, Antonio Voza, Simone Vanni, Claudio Bilato, Giovanna Geraci, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabio De Iaco, Fabrizio Oliva

{"title":"ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events.","authors":"Leonardo De Luca, Francesco Rocco Pugliese, Beniamino Susi, Alessandro Navazio, Marco Corda, Andrea Fabbri, Pietro Scicchitano, Antonio Voza, Simone Vanni, Claudio Bilato, Giovanna Geraci, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabio De Iaco, Fabrizio Oliva","doi":"10.1093/eurheartjsupp/suae033","DOIUrl":"10.1093/eurheartjsupp/suae033","url":null,"abstract":"In recent decades, an incredible evolution in antithrombotic therapies used for treating patients with atherosclerosis, atrial fibrillation, and venous thromboembolism has been observed, leading to the availability of increasingly safe drugs. Nonetheless, bleeding complications remain a significant concern, with considerable health, social, and economic implications. To improve the acute management of patients experiencing or at risk for major bleeding events, specific reversal agents for antithrombotic drugs have been recently developed. While these agents demonstrate effectiveness in small-scale pharmacodynamic studies and clinical trials, it is imperative to balance the benefits of reversing antiplatelet or anticoagulant therapy against the risk of prothrombotic effects. These risks include the potential loss of antithrombotic protection and the prothrombotic tendencies associated with bleeding, major surgery, or trauma. This joint document of the Italian Association of Hospital Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri) and the Italian Society of Emergency Medicine (Società Italiana di Medicina d'Emergenza-Urgenza) delineates the key features and efficacy of available reversal agents. It also provides practical flowcharts to guide their use in patients with active bleeding or those at elevated risk of major bleeding events.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on the simplification of the drug regimen for secondary cardiovascular prevention. 国家心脏病医生协会（ANMCO）关于简化心血管疾病二级预防用药方案的科学声明。

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-05-16 eCollection Date: 2024-04-01 DOI: 10.1093/eurheartjsupp/suae032

Leonardo De Luca, Stefania Angela Di Fusco, Gianmarco Iannopollo, Raffaella Mistrulli, Vittoria Rizzello, Alberto Aimo, Alessandro Navazio, Claudio Bilato, Marco Corda, Massimo Di Marco, Giovanna Geraci, Attilio Iacovoni, Massimo Milli, Vittorio Pascale, Carmine Riccio, Pietro Scicchitano, Emanuele Tizzani, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva

{"title":"Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on the simplification of the drug regimen for secondary cardiovascular prevention.","authors":"Leonardo De Luca, Stefania Angela Di Fusco, Gianmarco Iannopollo, Raffaella Mistrulli, Vittoria Rizzello, Alberto Aimo, Alessandro Navazio, Claudio Bilato, Marco Corda, Massimo Di Marco, Giovanna Geraci, Attilio Iacovoni, Massimo Milli, Vittorio Pascale, Carmine Riccio, Pietro Scicchitano, Emanuele Tizzani, Domenico Gabrielli, Massimo Grimaldi, Furio Colivicchi, Fabrizio Oliva","doi":"10.1093/eurheartjsupp/suae032","DOIUrl":"10.1093/eurheartjsupp/suae032","url":null,"abstract":"The issue of suboptimal drug regimen adherence in secondary cardiovascular prevention presents a significant barrier to improving patient outcomes. To address this, the utilization of drug combinations, specifically single pill combinations (SPCs) and polypills, was proposed as a strategy to simplify treatment regimens. This approach aims to enhance treatment accessibility, affordability, and adherence, thereby reducing healthcare costs and improving patient health. The document is an Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on simplifying drug regimens for secondary cardiovascular prevention. It discusses the underuse of treatments despite available, effective, and accessible options, highlighting a significant gap in secondary prevention across different socio-economic statuses and countries. The statement explores barriers to implementing evidence-based treatments, including patient, healthcare provider, and system-related challenges. The paper also reviews international guidelines, the role of SPCs and polypills in clinical practice, and their economic impact, advocating for their use in secondary prevention to improve patient outcomes and adherence.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the response to antihypertensive drugs heterogeneous? Rationale for personalized approach 对降压药物的反应是否具有异质性？采用个性化方法的理由

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-04-01 DOI: 10.1093/eurheartjsupp/suae019

M. Muselli, R. Bocale, S. Necozione, Giovambattista Desideri

{"title":"Is the response to antihypertensive drugs heterogeneous? Rationale for personalized approach","authors":"M. Muselli, R. Bocale, S. Necozione, Giovambattista Desideri","doi":"10.1093/eurheartjsupp/suae019","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suae019","url":null,"abstract":"\u0000 Arterial hypertension represents the most important cardiovascular risk factor with a direct responsibility for a large share of cardiovascular mortality and morbidity in the world. Despite the wide availability of antihypertensive therapies with documented effectiveness, blood pressure control still remains largely unsatisfactory in large segments of the population. Guidelines for the management of arterial hypertension suggest the preferential use of five classes of drugs—angiotensin-converting enzyme inhibitors, angiotensin II type I receptor inhibitors, calcium channel blockers, thiazide/thiazide-like diuretics, and beta-blockers—recommending the use of combination therapy, preferably in pre-established combinations, for the majority of hypertensive patients. The evidence of a non-negligible heterogeneity in the response to different antihypertensive drugs in different patients suggests the opportunity for personalization of treatment. The notable phenotypic heterogeneity of the population of hypertensive patients in terms of genetic structure, behavioural aspects, exposure to environmental factors, and disease history imposes the need to consider all the potential determinants of the response to a specific pharmacological treatment. The progressive digitalization of healthcare systems is making enormous quantities of data available for machine learning systems which will allow the development of management algorithms for truly personalized antihypertensive therapy in the near future.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for dilated cardiomyopathy in immediate family members: to whom, how, when (and where) 直系亲属扩张型心肌病筛查：筛查对象、筛查方式、筛查时间（以及筛查地点）

IF 1.6 4区医学

European Heart Journal Supplements Pub Date : 2024-04-01 DOI: 10.1093/eurheartjsupp/suae024

M. Pieroni, Michele Ciabattini, C. Zocchi

{"title":"Screening for dilated cardiomyopathy in immediate family members: to whom, how, when (and where)","authors":"M. Pieroni, Michele Ciabattini, C. Zocchi","doi":"10.1093/eurheartjsupp/suae024","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suae024","url":null,"abstract":"\u0000 Dilated cardiomyopathy (DCM) is defined by the presence of left ventricular dilation and systolic dysfunction in the absence of coronary artery disease, valvular disease, congenital heart disease, or altered haemodynamic conditions. Dilated cardiomyopathy can recognize multiple aetiologies, including infectious processes, effect of toxic substances, immunological mechanisms, and genetic causes. In recent years, many genes coding for proteins involved in the structure and function of the cardiomyocytes have been associated with the development of DCM, making the identification of familial forms increasingly frequent. At the same time, an ever-increasing use of cardiac magnetic resonance imaging has made it possible to identify early morpho-functional alterations in subjects with initial forms of the disease, or carriers of pathogenic genetic variants. The increasingly in-depth understanding of the genetic and molecular mechanisms operating in DCM has also favoured the development of new therapeutic strategies including drugs with molecular targets and gene therapies. In this panorama, screening of family members of patients affected by DCM represents an important tool for early diagnosis, treatment, and prognostic stratification. In relation to its clinical relevance and its complexity, it is important that family screening and follow-up of identified patients are carried out in units dedicated to the treatment and study of cardiomyopathies.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140772205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0